| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 06/07/2012 | US20120141555 Compound and device for treating bone and/or cartilage defects |
| 06/07/2012 | US20120141546 Oil-based preparation |
| 06/07/2012 | US20120141538 Modulators of the cx3cri receptor and therapeutic uses thereof |
| 06/07/2012 | US20120141531 Composition comprising oil drops |
| 06/07/2012 | US20120141513 Deuterated fingolimod |
| 06/07/2012 | US20120141511 Clostridial toxin derivatives able to modify peripheral sensory afferent functions |
| 06/07/2012 | US20120141510 Monomethylvaline compounds capable of conjugation to ligands |
| 06/07/2012 | US20120141509 Monomethylvaline compounds capable of conjugation to ligands |
| 06/07/2012 | US20120141508 Monomethylvaline compounds capable of conjugation to ligands |
| 06/07/2012 | US20120141507 Targeting of glycoprotein therapeutics |
| 06/07/2012 | US20120141506 Treatment of non-proliferative cystic disease |
| 06/07/2012 | US20120141505 Cd19-ligand and use |
| 06/07/2012 | US20120141499 Specific binding agents of human angiopoietin-2 |
| 06/07/2012 | US20120141498 Use of pkc isozymes for diagnosis and treatment of neuroblastoma |
| 06/07/2012 | US20120141496 Iap bir domain binding compounds |
| 06/07/2012 | US20120141491 Methods and compositions for the treatment of cancers and pathogenic infections |
| 06/07/2012 | US20120141483 Methods of treating or preventing psoriasis, and/or alzheimer's disease using indane acetic acid derivatives |
| 06/07/2012 | US20120141482 Molecular complexes which modify immune responses |
| 06/07/2012 | US20120141479 Histone Deacetylase Inhibitors Sensitize Cancer Cells To Epidermal Growth Factor Inhibitors |
| 06/07/2012 | US20120141475 TNF-alpha Antagonists and Methotrexate in the Treatment of TNF-Mediated Disease |
| 06/07/2012 | US20120141474 TNF-alpha Antagonists and Methotrexate in the Treatment of TNF-Mediated Disease |
| 06/07/2012 | US20120141470 T cell inhibitory receptor compositions and uses thereof |
| 06/07/2012 | US20120141468 Maintenance of platelet inhibition during antiplatelet therapy |
| 06/07/2012 | US20120141467 Ascorbic acid to treat chronic obstructive lung diseases and non-Hodgkin's lymphoma |
| 06/07/2012 | US20120141462 Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia |
| 06/07/2012 | US20120141459 Molecular targets for als and related disorders |
| 06/07/2012 | US20120141457 Lateral Flow Immunoassay for Complement Activation and Methods of Use for Point-of-Care Assessment of Complement-Associated Disorders |
| 06/07/2012 | US20120141454 Methods of Use of Inhibitors of Phosphodiesterases and Modulators of Nitric Oxide, Reactive Oxygen Species, and Metalloproteinases in the Treatment of Peyronie's Disease, Arteriosclerosis and Other Fibrotic Diseases |
| 06/07/2012 | US20120141453 Glycosidase Enzymes |
| 06/07/2012 | US20120141452 Targeted Therapeutic Proteins |
| 06/07/2012 | US20120141451 Fibroblast growth factor receptor-derived peptides binding to ncam |
| 06/07/2012 | US20120141450 Risk markers for cardiovascular disease |
| 06/07/2012 | US20120141449 Albumin Fusion Proteins |
| 06/07/2012 | US20120141448 Method for increasing muscle mass and strength |
| 06/07/2012 | US20120141433 Vaporized Stem Cell Derivatives for Topical and Other Therapeutic Uses |
| 06/07/2012 | US20120141430 Tissue Regeneration Membrane |
| 06/07/2012 | US20120141424 Materials and Methods for the Treatment of Hypertension |
| 06/07/2012 | US20120141419 Biodegradable Linkers for Molecular Therapies |
| 06/07/2012 | US20120141417 Collagen Preparation and Method of Isolation |
| 06/07/2012 | US20120141415 Albumin Fusion Proteins |
| 06/07/2012 | US20120141414 Bimacrocylic HCV NS3 Protease Inhibitors |
| 06/07/2012 | US20120141413 Use of il-15 preparations to treat lymphopenia |
| 06/07/2012 | US20120141412 Methods of treating idiopathic thrombocytopenic purpura with compositions comprising extracts of astragalus membranaceus |
| 06/07/2012 | US20120141411 Uses of IL-174 Antagonists for Inhibiting A Th2 Immune Response |
| 06/07/2012 | US20120141410 Method and composition for the treatment of moderate to severe keratoconjunctivitis sicca |
| 06/07/2012 | US20120141380 Polymer nanoparticles coated by magnetic metal oxide and uses thereof |
| 06/07/2012 | US20120141377 Compositions and methods for treating cancer |
| 06/07/2012 | US20120141376 Prostate specific transcripts and the use thereof for prostate cancer therapeutics and diagnostics |
| 06/07/2012 | CA2819608A1 Novel cyclosporin derivatives for the treatment and prevention of a viral infection |
| 06/07/2012 | CA2819463A1 Tomm34 peptides and vaccines including the same |
| 06/07/2012 | CA2819206A1 Use of pacap for treating viral infections in aquatic organisms |
| 06/07/2012 | CA2818067A1 New treatments of hepatitis c virus infection |
| 06/07/2012 | CA2817773A1 Methods for increasing intracellular activity of hsp70 |
| 06/07/2012 | CA2814595A1 Anticancer fusion protein |
| 06/07/2012 | CA2812348A1 Egfr antagonist for the treatment of heart disease |
| 06/07/2012 | CA2812102A1 Biodegradable drug delivery composition |
| 06/06/2012 | EP2460881A1 Proteoglycan degrading mutants for treatment of CNS |
| 06/06/2012 | EP2460826A1 Motilin-like peptide compound having transmucosal absorbability imparted thereto |
| 06/06/2012 | EP2460825A1 Derivative of glp-1 analogue or its pharmaceutical salts and their use |
| 06/06/2012 | EP2460814A1 Peptidic compound and use of same |
| 06/06/2012 | EP2460542A1 Pancreatic endocrine cell indicator and utilization of same |
| 06/06/2012 | EP2460537A1 Methods for treating conditions associated with MASP-2 dependent complement activation |
| 06/06/2012 | EP2460534A1 Flagellin related polypeptides and uses thereof |
| 06/06/2012 | EP2460532A1 Chemical method for sexual sterilisation and libido suppression in male mammals |
| 06/06/2012 | EP2460531A1 Collagen for use in the treatment of skin ailments |
| 06/06/2012 | EP2460530A2 Human growth hormone crystals and methods for preparing them |
| 06/06/2012 | EP2460529A1 Therapeutic agent and therapeutic method for periodontal diseases and pulpal diseases |
| 06/06/2012 | EP2460528A1 Therapeutic agent and therapeutic method for periodontal diseases and pulpal diseases |
| 06/06/2012 | EP2460527A1 Pharmaceutical composition for treating a metabolic syndrome |
| 06/06/2012 | EP2460515A1 Oral calcitonin compositions and applications thereof |
| 06/06/2012 | EP2459589A1 Mutants pf4 polypeptides exhibiting an increased anti-angiogenic activity |
| 06/06/2012 | EP2459584A1 Homing peptide for tumor vasculature |
| 06/06/2012 | EP2459582A1 Hepatitis c virus ns3 protease inhibitors |
| 06/06/2012 | EP2459233A1 Adipose-derived stromal cells (asc) as delivery tool for treatment of cancer |
| 06/06/2012 | EP2459228A1 Prodrugs comprising an insulin linker conjugate |
| 06/06/2012 | EP2459213A1 Polypeptides that bind tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods |
| 06/06/2012 | EP2459212A1 Compositions and methods for treating gaucher disease |
| 06/06/2012 | EP2459211A1 Continuous subcutaneous administration of interferon- to hepatitis c infected patients |
| 06/06/2012 | EP2459210A1 Methods for diagnosing or predicting hepatitis c outcome in hcv infected patients |
| 06/06/2012 | EP2459209A2 Broad spectrum erbb ligand binding molecules and methods for preparing and using them |
| 06/06/2012 | EP2459208A2 Therapeutic agents for reducing parathyroid hormone levels |
| 06/06/2012 | EP2459207A2 Pharmaceutical composition for treating medical conditions and a method for treating alimentary disorders and related diseases |
| 06/06/2012 | EP2459183A1 Methods for treatment of pain |
| 06/06/2012 | EP2458990A1 Methods for producing high concentration lyophilized pharmaceutical formulations |
| 06/06/2012 | EP2261374B1 Method of preventing virus:cell fusion by inhibiting the function of the fusion initiation region in RNA viruses having Class I membrane fusogenic envelope proteins |
| 06/06/2012 | EP2240155B1 Devices, formulations, and methods for delivery of multiple beneficial agents |
| 06/06/2012 | EP2196475B1 INTERFERON ALPHA 2a MODIFIED BY POLYETHYLENE GLYCOL, ITS SYNTHESIS PROCESS AND APPLICATION |
| 06/06/2012 | EP2126064B1 Mek ligands and polynucleotides encoding mek ligands |
| 06/06/2012 | EP2004693B1 Compositions and methods of use for antibodies of c-met |
| 06/06/2012 | EP1831254B1 Conjugation product |
| 06/06/2012 | EP1799865B1 Methods for the administration of iloperidone |
| 06/06/2012 | EP1787653B1 Antitumoral pharmaceutical composition containing polypeptide fragments of serralysins |
| 06/06/2012 | EP1716235B1 Inhibitors of tgf-r signaling for treatment of cns disorders |
| 06/06/2012 | EP1709075B1 Treatment of viral infections |
| 06/06/2012 | EP1667708B1 POLYETHYLENE GLYCOL CONJUGATES OF INTERFERON-BETA-1b WITH ENHANCED IN VITRO BIOLOGICAL POTENCY |
| 06/06/2012 | EP1663291B1 Recombinant lubricin molecules and uses thereof |
| 06/06/2012 | EP1661579B1 Method for treating systemic bacterial infection associated with changes of qualitative and/or quantitative composition of blood extracellular dna |
| 06/06/2012 | EP1628530B1 Methods and compositions for the prevention and treatment of sepsis |
| 06/06/2012 | EP1616575B1 Method for treating inflammation |
| 06/06/2012 | EP1575526B1 Dna vaccines encoding heat shock proteins |